SPONSORED CONTENT Essilor® Stellest® Lenses When it comes to children’s myopia management, it’s important to look beyond correction alone. Essilor® Stellest® Lenses are the first and only FDA market authorized spectacle lens to slow myopia progression in children¹. The effectiveness of the Essilor® Stellest® Lens is evidenced by clinical data showing Essilor® Stellest® Lenses slowed myopia progression by 71% on average over 2 years*². Essilor® Stellest® Lenses slow myopia progression in children,*² with H.A.L.T.† technology: a constellation of invisible‡ lenslets. This design creates a volume of myopic defocus that follows the shape of the retina, providing a consistent treatment signal for the retina across all gaze directions intended to slow eye elongation. As an eye care professional, expand your myopia management toolkit with the only FDA market authorized spectacle lens for slowing myopia progression in children¹. Bring trusted, science-backed innovation into your practice by choosing Essilor® Stellest® Lenses. Learn more * Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment. † H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression. ‡ Aesthetic finish 1. U.S. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia. Sep 2025. 2. Essilor International, data on file (2025) Click here
